Author:
Jacobson Kenneth A.,Oliva Paola,Suresh R. Rama
Publisher
Springer International Publishing
Reference103 articles.
1. Borea PA, Varani K, Vincenzi F, Baraldi PG, Tabrizi MA, Merighi S et al (2015) The A3 adenosine receptor: history and perspectives. Pharmacol Rev 67(1):74–102
2. Jacobson KA, Tosh DK, Gao ZG, Yu J, Suresh RR, Rao H, Romagnoli R, Baraldi PG, Tabrizi MA (2018) Chapter 7. Medicinal chemistry of the A3 adenosine receptor. In: Varani K (ed) The adenosine receptors, the receptors, vol 34. Springer, pp 169–198. https://doi.org/10.1007/978-3-319-90808-3_7
3. Merighi S, Battistello E, Giacomelli L, Varani K, Vincenzi F, Borea PA et al (2019) Targeting A3 and A2A adenosine receptors in the fight against cancer. Expert Opin Ther Targets:1–10. https://doi.org/10.1080/14728222.2019.1630380
4. David M, Gospodinov DK, Gheorghe N et al (2016) Treatment of plaque-type psoriasis with oral CF101: data from a phase II/III multicenter, randomized, controlled trial. J Drugs Dermatol 15(8):931–938
5. Safadi R, Braun M, Francis A et al (2021) Randomised clinical trial: a phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. Aliment Pharmacol Ther 54:1405–1415. https://doi.org/10.1111/apt.16664